Although continuous BTK inhibitors have the most prospective data for high-risk CLL (17p/TP53 mutations), some highly motivated patients still opt for fixed-duration treatment. This requires a detailed conversation where clinicians must explain the trade-off: achieving a treatment-free period may come at the cost of needing second-line therapy sooner.

A common assumption that older patients may prefer simpler, continuous medication regimens is often incorrect. Clinical experience shows that the vast majority of patients, regardless of age, are interested in a time-limited therapy option, provided it can be delivered conveniently without infusions.

Adding obinutuzumab later to acalabrutinib/venetoclax therapy—and only for patients with an incomplete response—achieves the same remission rates as upfront administration. This delayed approach improves overall survival by avoiding early, severe infections, particularly COVID-19, associated with the antibody.

The study utilized "interruption-free survival" as a primary endpoint, a pragmatic measure derived from real-world data. This serves as a valuable surrogate for treatment toxicity, as clinicians typically pause treatment in response to adverse events, providing a quantifiable measure of a drug's real-world tolerability.

Traditional endpoints like progression-free survival (PFS) incentivize continuous treatment. The NCI group proposes "treatment-free survival," a novel metric that quantifies time spent *off* therapy. This endpoint better captures the patient experience and rewards treatments that provide durable responses after a finite course.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

The CLL17 study reveals that continuous ibrutinib, fixed-duration venetoclax/obinutuzumab, and fixed-duration venetoclax/ibrutinib all yield identical progression-free survival rates at three years. This finding empowers clinicians to choose a strategy based on patient preference (continuous vs. fixed-duration) without compromising near-term efficacy.

Data shows that patients who permanently stopped ipilimumab due to immune-related side effects still had exceptionally good outcomes. This gives clinicians confidence to manage toxicity by discontinuing the CTLA-4 inhibitor portion of the regimen while continuing nivolumab, without fearing a loss of efficacy.

While many CLL patients prefer fixed-duration therapy to avoid continuous medication, this preference is often overridden by practical logistics. The burden of increased monitoring and frequent clinic visits associated with fixed-duration regimens leads some patients to opt for continuous therapy instead.